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(57) ABSTRACT 
A method to analyze and diagnose specific bacteria in a 
biologic sample using spectroscopy is disclosed. The 
method includes obtaining the spectra of a biologic sample 
of a non-infected patient for use as a reference, subtracting 
the reference from the spectra of an infected sample, and 
comparing the fingerprint regions of the resulting differential 
spectrum with reference spectra of bacteria in saline. Using 
this diagnostic technique, specific bacteria can be identified 
sooner and without culturing, bacteria-specific antibiotics 
can be prescribed sooner, resulting in decreased likelihood 
of antibiotic resistance and an overall reduction of medical 
costs. 
26 Claims, 3 Drawing Sheets 
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SPECTROSCOPIC DIAGNOSTICS FOR 
BACTERIA IN BIOLOGIC SAMPLE 
2 
to improve over a few days. In cases where a specific 
bacterial diagnosis is impossible, treatment with broad spec-
trum antibiotics is continued. 
There is a growing concern in the medical field over This application claims priority to U.S. provisional appli-
cation no. 60/145,522, filed on Jul. 24, 1999. 
This invention is the subject of a grant from the United 
States Department of Energy, Grant No. 
#DEFG0297ER14799. The U.S. government may have cer-
tain rights in this invention. 
5 developing antibiotic resistance. Bacteria can develop resis-
tance to antibiotics when they are exposed to them through 
several mechanisms. They also have the ability to pass this 
resistance on to other bacteria that have not been exposed to 
the antibiotic. As a result, physicians prefer to use the 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
10 simplest antibiotic necessary to treat an infection, thus 
reducing the exposure of bacteria to stronger antibiotics and 
theoretically reducing the rate of resistance. 
The present invention relates to using spectroscopic meth-
ods in medical diagnostics to analyze and diagnose specific 
bacteria in a biologic sample. Using this diagnostic 15 
technique, specific bacteria can be identified sooner and 
without culturing, and bacteria-specific antibiotics can be 
prescribed sooner, resulting in an earlier, more accurate 
diagnosis of infection and corresponding antibiotic 
prescription, decreased likelihood of antibiotic resistance 20 
and an overall reduction of medical costs. 
Therefore, there exists a need in the art for methods for 
rapidly diagnosing bacteria, thus improving patient care by 
providing targeted antibiotic therapy earlier. Rapid diagnos-
tic tests can decrease antibiotic resistance by decreasing the 
use of broad spectrum and ineffective antibiotics. Medical 
costs may also be lowered since fewer prescriptions would 
be changed during treatment. 
2. Prior Art 
Some spectroscopic techniques already known in the art 
have been adapted for use in medical diagnostics, none of 
which provides the advantages of the present invention. For 
Middle ear infection, or otitis media (OM), is the most 
frequent diagnosis in children. Seventy-five percent of chil-
dren under age three experience at least one episode of otitis 
media, while almost half of those children will have three or 
more infections. 
OM accounts for almost 46% of the more than 48 million 
annual prescriptions in the United States. The estimated cost 
of treating OM is about $5 billion annually. 
25 example, WO 97/48329 discloses a method for diagnosing 
cervical precancer using near infrared Raman spectroscopy. 
Additionally, several spectroscopic techniques are already 
used to detect bacteria in isolated samples. 
Goodacre et al. disclose the use of pyrolysis mass spec-
30 trometry (PyMS), Fourier transform infrared spectroscopy 
(FTIR) and dispersive Raman microscopy to analyze a 
group of bacterial isolates associated with urinary tract 
infections. (Microbiology May 1998, 144 (Pt.5): 1157-70). 
OM is a bacterial infection that results in inflammation of 
the inner ear and an accumulation of fluid behind the 
eardrum. Usually resulting from a bacterial or viral infection 
secondary to a cold, sore throat, or other respiratory 
infection, OM is usually treated with antibiotics. A diagnosis 35 
of the specific bacteria results in targeted treatment by 
helping physicians prescribe an antibiotic effective for the 
particular bacteria. 
Current medical methods used to diagnose bacterial 
organisms normally require at least one day. In addition, 40 
physicians often need to determine bacteria resistance to 
antibiotics, and this determination routinely takes another 
day. Gram staining, analyzing organisms from a sample 
visually with a microscope, may provide a rough estimate of 
the most likely organism, but this process can be inaccurate. 45 
This is especially so for one of the bacteria common to OM, 
Haemophillus influenzae. Thus, after a presumptive diagno-
sis from gram staining, the bacteria are cultured for at least 
a day and identified. This time-intensive process follows the 
difficulty of acquiring the sample from the patient. The 50 
methods of collection depend on the site of infection. Some 
are readily accessible, such as urine, however some samples 
require invasive procedures which can be quite painful, 
including, in the case of OM, piercing the eardrum to 
withdraw infected fluid. Additionally and unavoidably, some 55 
samples are collected after the patient has begun antibiotic 
treatment, making diagnosis of the bacteria organism diffi-
cult or impossible. 
Because of the delay in specific bacterial diagnosis and 
the pain suffered by the patient, physicians usually prescribe 60 
broad spectrum antibiotics that can cover a wide variety of 
bacteria until the specific strain of bacteria is identified. 
After identification, the antibiotics are usually changed to 
those necessary to treat the infection. In the case of OM, the 
physician will treat with antibiotics to cover the most likely 65 
organisms, and if the organism is resistant to the antibiotic, 
the physician will change the antibiotic after the patient fails 
WO 98/41842 discloses a system for the detection of 
bacteria antibody complexes using UV resonance Raman 
spectroscopy. The system uses Raman spectroscopy to cre-
ate a characteristic spectral peak of a microorganism ana-
lyzed from an antibody complex. 
Werkhaven et al. disclose that an optical window that will 
transmit sufficient light for in vivo measurement of fluores-
cence profiles has been found in the chinchilla tympanic 
membrane. (Laryngoscope March 1994; 104(3 pt. 1): 
264-8). 
Sorrell et al. disclose that fluorescence profiles of four 
common pathogens have been determined and are reproduc-
ible. (Lasers Surg Med 1994; 14(2): 155-63. 
Timmins et al. disclose that distinct fingerprints for three 
Candida species are consistent with reference isolates. (J. 
Clin. Microbial. February 1998, 36(2): 367-74). 
In the above studies, the identification of bacteria using 
Fourier-transfer infrared spectroscopy (FTIR) has only been 
demonstrated for isolated bacteria after they have been 
cultured and purified. The ability of FTIR spectroscopy to 
detect bacteria in biologic fluid has not, heretofore, been 
investigated. 
Biologic fluid has absorption bands that greatly overlap 
the regions useful in differentiating the differences in bac-
teria. Such overlap would greatly change the previous gen-
eral analysis and conclusions of the spectroscopic tech-
niques. Furthermore, the biologic fluid might interact 
chemically with the chemicals in the bacteria or alter the 
local environment of the bacteria (i.e., by changing the pH) 
sufficiently to alter the spectra of the bacteria and make them 
unrecognizable when compared to their pure spectra. 
Therefore, it is necessary to be able to study the spectra of 
the bacteria in the biologic fluid, that is, in samples taken 
US 6,379,920 Bl 
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directly from the patient. In addition, it becomes more 
practical to analyze the spectra of bacteria within the context 
of one disease entity at a time. This specifies the nature of 
the medium and simplifies data interpretation by limiting the 
number of possible pathogens. None of the above-described 5 
techniques address these considerations. 
The present invention, on the other hand, is directed to a 
method for using spectroscopy in the identification of spe-
cific bacteria in a biologic sample. Preferably, FTIR is used 
to detect the three most common bacteria in otitis media 10 
(OM), Streptococcus pneumoniae (SP), Haemophilus influ-
enzae (HI) and Morazella catarrhalis (MC). 
SUMMARY OF THE INVENTION 
Briefly described, in a preferred form, the object of the 
present invention is to provide a method for the diagnosis of 
15 
a bacterial organism in a biologic fluid using spectroscopic 
techniques. Preferably, FTIR, fluorescence and Raman spec-
troscopy are used as medical diagnostics to detect the three 20 
most common bacteria in otitis media (OM), Streptococcus 
pneumoniae (SP), Haemophilus influenzae (HI) and Mora-
zella catarrhalis (MC). 
It is a further object of this invention to provide a 
diagnostic method for detecting specific strains of bacteria in 25 
a biologic sample without subjecting the sample to cultur-
ing. Preferably, FTIR, fluorescence and Raman spectroscopy 
are used to detect bacteria. More preferably, FTIR is used to 
diagnose the bacteria. 
4 
(MC), and (c) Streptococcus pneumoniae (SP) and for (d) 
serum in the spectral region of 4000-800 cm-1 . 
FIG. 2a is a graph of absorbance versus wavelength which 
depicts the three bacterial species (a) Haemophilus influen-
zae (HI), (b) Morazella catarrhalis (MC), and (c) Strepto-
coccus pneumoniae (SP) in direct comparison with their 
"row" infrared (IR) absorption in the region of 1800 and 
1700 cm-1 . 
FIG. 2b depicts the three bacterial species (a) Haemophi-
lus influenzae (HI), (b) Morazella catarrhalis (MC), and (c) 
Streptococcus pneumoniae (SP) in direct comparison with 
their infrared (IR) absorption after application of a function 
f(n), which increases the intensity of the lower frequency 
bands in the fingerprint region. 
FIG. 3a is a graph of absorbance versus wavelength which 
shows the spectral comparison of the serum and each 
bacterium in the presence of the serum in the spectral region 
of 1500--950 cm-1 . 
FIG. 3b depicts the difference spectra in the region of 
1500-950 cm-1 of each bacterium when compared with the 
pure bacteria spectra. 
FIG. 3c depicts the pure bacteria spectra in the region of 
1500-950 cm-1 . 
DETAILED DESCRIPTION OF THE 
PREFERRED EMBODIMENT 
It is another object of the present invention to improve the 30 
treatment of infectious diseases by providing a rapid strain-
specific bacterial diagnosis. By increasing the speed of 
diagnosis of the specific strain, a doctor may immediately 
begin targeted treatment of the infection with an antibiotic 
specific to that strain. 
These objects have been achieved by using spectroscopic 
techniques such as FTIR, fluorescence and Raman spectros-
copy to compare the known spectra of particular bacteria 
strains with the spectrum determined from a biologic sample 
and subtracting the spectrum of pure serum. 
A rapid test to identify bacteria causing infections while 
still submerged in biologic fluid has been discovered using 
spectroscopy, including Fourier Transfer Infrared Spectros-
copy (FTIR), fluorescence or Raman spectroscopy. Spectro-
scopic techniques can be used to significantly decrease the 
processing time of samples from the moment a sample is 
collected until the time a diagnosis can be made. Once the 
35 
spectral regions useful for identification are determined, it is 
possible to develop both noninvasive and invasive tech-
niques for diagnosing organisms while still in the body using 
laser-fiber optic methodology. 
40 For example, spectroscopic techniques can be incorpo-
More particularly, the present invention is directed to a 
method for diagnosing bacteria in a biologic sample com-
prising analyzing a sample of infected serum with a 
spectrometer, subtracting the spectrum of a previously-
obtained reference serum from the spectra of the infected 45 
serum, and comparing the resulting differential spectra with 
reference spectra of bacteria in saline to determine the 
specific bacteria present in the sample. 
It has been found that using our spectroscopic techniques, 50 
a rapid determination of the specific bacterial strains can be 
made, thus allowing for targeted treatment and avoiding the 
use of broad spectrum antibiotics. Such targeted treatment 
eliminates the medical costs associated with prescribing 
broad spectrum antibiotics and then represcribing antibiotics 55 
specific to the infection. Additionally, targeted treatment 
reduces the likelihood of the patient developing antibiotic 
resistance. 
rated into rapid, automated systems that can process large 
numbers of cultured bacteria from any collected sample. 
Additionally, bacteria can be diagnosed in freshly collected 
samples while still contained in fluid from the human body, 
for example middle ear aspirates, pus, pleural effusions, 
synovial fluid, abscesses or cavity swabs. It is also possible 
to diagnose microorganisms in body cavities using spectro-
scopic techniques by passing and receiving the optical signal 
through epithelial tissues using fiberoptic systems. Spectro-
scopic techniques can also be integrated into fiberoptic 
instruments such as endoscopes, bronchoscopes, arthro-
scopes and flexible endoscopes used in gastrointestinal and 
colonoscopy procedures to detect infection in the body 
cavity. 
Using the method of the present invention, a laser spec-
troscopic technique for identifying bacteria in vivo can be 
developed. The laser is passed through a fiber optic system, 
and the signal is received through the same system. Using 
the spectroscopic regions determined by the method of the These and other objects, features, and advantages of the 
present invention will become more apparent upon reading 
the following specification in conjunction with the accom-
panying drawing figures. 
60 present invention, bacteria can be distinguished from other 
bacteria and from bodily fluids. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a graph of absorbance versus wavelength which 
shows the FTIR spectra of the three bacterial dry films (a) 
Haemophilus influenzae (HI), (b) Morazella catarrhalis 
Additionally, the unique regions for each bacterium dis-
covered through the process of the present invention can be 
incorporated into an automated system to identify bacteria 
65 more quickly. Such automation would eliminate the need for 
bacteria culturing and allow for rapid diagnosis using only 
a small sample. 
US 6,379,920 Bl 
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Spectroscopic methods of diagnosis are known to be rapid 
and can be automated to test multiple samples at a time. 
Fluorescence, absorption in the ultraviolet (UV), visible and 
infrared (IR) regions and laser Raman spectroscopy are the 
most common spectroscopic techniques and are all contem-
plated for use in the method of the present invention. 
6 
frank pus with many inflammatory cells, products and 
debris. OME can result after an episode of AOM or develop 
on its own with a silent onset, and the fluid can range from 
a watery serous effusion to a viscous form containing mucin. 
5 Three bacteria are most consistently cultured from sampled 
effusions of AOM and OME: Streptococcus Pneumonia 
(SP), Haemophilus Influenza (HI) and Moraxella Catarhal-
lis (MC). In this example, we examined the FTIR spectra of 
these bacteria in blood serum. 
A preferred embodiment of the present invention is the 
use of FTIR to diagnose bacteria in a biologic sample. FTIR 
offers a rapid, inexpensive, accurate and potentially auto-
mated method for the detection of bacteria. FTIR spectros- 10 
copy provides a fingerprint spectrum of molecules based on 
the vibration of the chemical bonds present that is specific to 
the structure of those molecules in a given substance. Using 
cluster analyses or artificial neural network analyses or 
developing a database of known bacterial spectra, a rapid, 15 
automated system may be used to identify bacteria isolated 
Sample: Three bacterial species grown in culture broth, 
HI (ATCC 49247), SP (ATCC 046196), MC (clinical 
isolate), and blood serum collected from a healthy volunteer 
in a standard fashion and stored frozen, were used for this 
study. The final bacteria concentration were estimated to be 
1.2xl06 cell/ml, in physiological saline. This was compa-
rable to the concentration of bacteria in the fluid of infected 
persons. The mixtures of each bacterial species with blood 
serum were prepared at volume ration of 1:1. Here bacte-
rium was at the above concentration and the blood serum 
in clinical settings. 
20 was at the original concentration as separated from the blood 
sample from the volunteer. This resultant final concentration 
of bacteria in serum was 8.0x105 cells/cm2 . 
Bacteria represent a large population of organisms com-
prised of many different species. Since bacteria are biologic 
cellular organisms, they contain many chemicals in common 
with other cellular organisms such as amino acids, nucle-
otides and polysaccharides. The human body also contains 
many of these chemicals within its cells as well as in the 
extracellular space. Thus, many bodily fluids are expected to 
contain chemicals that are similar to those found in bacteria. 
Spectroscopically, this means that it is expected that many 
features in the spectroscopic analysis will appear similar 
when comparing different bacteria and when comparing 
human cells and bodily fluid. However, distinctions between 
each bacteria and between bacteria and human cells do exist. 30 
A droplet of -0.2 ml from each sample at the above 
concentrations was placed on a ZnSe plate to make an area 
25 of -0.5 cm2 . To remove spectral interference from water, 
samples were dried overnight at room temperature and then 
heated at 50° C. for -10 minutes for further dehydration. The 
samples of pure serum, isolated bacteria, and mixtures of 
serum and bacteria were prepared in the same manner. 
FTIR spectroscopy: A Bruker IFS66/S infrared spectrom-
eter was used, with a DTGS detector used for the mid- to 
far-IR region. All spectra were the average of 100 scans at 
a resolution of 2 cm-1 . Baseline correction and spectral 
subtraction were obtained using OPUS 2.0 software pro-
The ability to exploit these differences in a manner which 
makes them detectable is the subject of the present inven-
tion. 
Changes in the local environment of a chemical, in the 
sequence of an amino acid, or even in the relative ratio of 
one chemical to another in a specific bacteria may be 
detected spectroscopically. These differences can be 
exploited to identify individual bacteria. 
Bacteria can be sampled from many forms of biologic 
sera. For example, middle ear aspirate can be obtained by 
tympanocentesis, saliva can be obtained through swabbing 
or sampling, or blood can be drawn. Examples of biologic 
fluids useful in the method of the present invention include, 
but are not limited to, blood, urine, middle ear aspirate, bile, 
vaginal secretions, pus, pleural effusions, synovial fluid, 
abdominal cavity abscesses, and saliva. 
The following examples are designed to study one disease 
process at a time, merely for ease in data interpretation. In 
the same manner that a physician selects the most likely 
organisms to begin treatment, analysis of spectra can be 
simplified by reducing the number of expected possible 
bacteria to the common bacteria that cause a certain disease. 
In this manner, analysis algorithms for each disease can be 
developed. 
The following examples are provided to demonstrate the 
present invention and are not intended to limit its scope in 
any way. 
EXAMPLE I 
Otitis media (OM) is one of the most common infectious 
diseases. Treatment of OM is estimated at $5 billion annu-
ally in the United States. OM represents an infection in the 
middle ear, behind the tympanic membrane, and can exist as 
an acute otitis media (AOM) or as a chronic nonpurulent 
effusion known as otitis media with effusion (OME). The 
fluid of AOM can range from a watery serous effusion to 
35 vided by Bruker. Spectral subtraction between the 
bacterium-serum mixture and pure serum was judged by 
selecting a specific band only found in blood serum and 
ensuring that this band had completely disappeared in the 
difference spectrum. The chosen band was at 1307 cm-1, and 
40 it was not present in the spectra of any of the bacteria. 
Results: Steady-state spectra: FIG. 1 shows the FTIR 
spectra of the three bacterial dry films, HI (a), MC (b), and 
SP (c), and for serum (d) in the spectral region of 4000--800 
cm-1 . Three common spectral features were found: a broad 
45 band at 3300 cm-1 (which can be assigned to the well-
known amide A band, resulting from the N-H stretching 
vibration of polypeptide chain); two bands at 1651 cm-1 and 
1540 cm-1 , which can be assigned to the amide I and II 
modes of the protein, respectively. These band features are 
50 associated with the cellular proteins. The observed bands 
between 1300 and 800 cm-1 can be attributed to the specific 
absorption of the phosphate groups and possible oligo- and 
polysaccharides of the cell wall (van der Meir). The DNN 
RNA oligo- and polynucleotides (base-ring vibrations of 
55 guanine, thymine, adenine, cytosine and uracil) were also 
observed in the region between 1700-1200 cm-1 . Possible 
band assignment of these compounds in bacteria has been 
reported previously in a Raman study by Naumann. A 
careful comparison of the spectra in this region could serve 
60 as a fingerprint for each bacterium since their chemical 
composition is not exactly the same. The blood serum in 
FIG. 1 has a similar spectral feature as those for bacteria. 
There is almost a one-to-one correlation between the four 
spectra shown in FIG. 1. However, significant difference 
65 does exist in the fingerprint region. For example, the band at 
1307 cm-1 is a unique band for serum. This band is used in 
the spectral subtraction of the serum spectrum from the 
US 6,379,920 Bl 
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spectra of the bacteria in serum in order to characterize the 
spectra of the different bacteria in the serum medium (as a 
biologic fluid). 
8 
FIG. 3a shows the spectral comparison of the serum and 
each bacterium in the presence of the serum in the spectral 
region of 1500-950 cm-1 . In this region, the original bands 
and their positions for each bacterium were still observable. As shown in FIGS. 2a and 2b, these three bacteria species 
can be easily identified by direct comparison of their IR 
absorption. The mixture of bacteria and serum will be 
presented in Example II below. 
Comparison of the fingerprint region: FIG. 2a shows the 
direct comparison of the "row" spectra of the three bacteria 
in the region of 1800 and 1700 cm-1 . The important char-
acteristic differences in the spectra of these bacteria in this 
region are as follows: 
5 In other words, bacteria do not lose their IR band features, 
even when mixed with serum. The contribution of serum in 
the infrared spectrum may be subtracted in order to reveal 
the typical fingerprints of each bacterium. The criteria for a 
complete removal of blood serum was measured by the 
1. A distinction between HI and the other two bacteria can 
10 disappearance of the band at -1308 cm-1 , which is unique 
for serum, as shown in FIG. 1. The band at -1239 cm-1 
could also be used as an additional band since the relative 
intensity of these two bands is comparable in the case of 
be made from the large difference in the intensity of the 
band in the 1000--1150 cm-1 region. This band is more 15 
intense for the HI than for either SP or MC. For 
blood serum, whereas it is not in the case of the three 
bacteria (FIG. 1). The band at -1239 cm-1 is relatively weak 
in the spectrum of each bacterium. 
In FIG. 3b, the difference spectra in the region of 
1500-950 cm-1 clearly show the original band features of 
each bacterium when compared with the pure bacteria 
example, for HI, the relative intensity of this band to the 
bands in the 1200-1300 cm-1 region is more than 2, 
and almost 3. For MC, this ratio is slightly greater than 
one. 
2. In order to distinguish between SP and MC, the FTIR 
spectrum of SP bacterium is characterized by being 
sharper (better resolved) in the 1100-1000 cm-1 , and 
the amide I band (in the 1620-1660 cm-1 region) of the 
SP bacterium is split (again due to its higher resolved 
sharper spectrum). In order to enhance the relative 
intensity of the fingerprint region in the 1100-1000 
cm-1 , relative to the more intense amide bands in the 
1700-1500 cm-1 region, each of the spectrum in FIG. 
20 spectra (shown in FIG. 2b). This study demonstrates that no 
significant spectroscopic reaction occurs between the serum 
and the bacteria as demonstrated by the additivity of their 
FTIR spectra. This result demonstrates that one is able to 
distinguish these three bacteria in the presence of blood 
25 serum. A simple method for rapid identification of bacteria 
in blood serum is thus possible. 
2a is multiplied by a function, f(n), that increases the 30 
intensity of the lower frequency bands more than the 
higher frequency ones: f(n)=(l.7-n/lOOO)xlOO. After 
applying this function to the absorbance, An, at fre-
quency n of each bacterium, the new absorbance, An*, 
becomes An*=Anx f(n). This is applicable in the fre- 35 
quency range between 1700 and 1000 cm-1 . By apply-
ing this function, the enhanced spectra are shown in 
FIG. 2b. It is shown that after this treatment, the 
spectral difference becomes more obvious. Three band 
groups are labeled as I, II and III. In group I, there is 40 
only an unresolved broad band for HI and MC, whereas 
there are a few distinct bands for SP, at 1077, 1057 and 
1029 cm-1 . In the band groups II and III, the band 
maximum is different in these species, as shown in the 
figure: 1250 cm-1 (HI), 1233 cm-1 (MC and SP). There 45 
is also a band shape and band position difference in 
group III, -1393 cm-1 for HI, and -1379 cm-1 for MC 
and SP. 
EXAMPLE II 
In order to see if the signatures differentiating the spectra 
of the different bacteria persist in biologic fluid, the spectra 
50 
of these bacteria were taken in serum. The spectrum of pure 
serum previously obtained was then subtracted from the 
spectra of the samples containing bacteria mixed in serum 55 
and the remaining spectra were then compared with the 
spectra of bacteria in saline shown in FIG. 2a. 
Bacteria and serum have similar band features in the 
region of 4000--800 cm-1, as shown in FIG. 1. Efforts have 
been made to characterize the bacteria in the environment of 60 
blood serum. As described in the experimental section, the 
mixture of bacterium and serum contains 1:1 volume ratio of 
the concentrated bacterial solutions (-1.2xl06 cell/ml) and 
the original serum extracted from the blood that is donated 
by a healthy volunteer. Dry films were made by controlled 65 
amounts of aqueous solutions containing mixtures of each 
bacterium with the blood serum. 
From the above results, it is concluded that in the FTIR 
spectra of dry film, each bacterium has a typical band feature 
in the region of 700--1800 cm-1 . Furthermore, the spectra 
were found not to change when the bacteria are present in 
serum (which mimics the biologic fluid). Three groups were 
analyzed and could serve as the fingerprints for the rapid 
identification and characterization. The identification can be 
carried out visually for small groups of bacteria, or better 
yet, with a software program that analyzes the relative 
intensities, band shapes and frequencies in this region. This 
will give much better statistics and thus higher confidence 
factors for the diagnosis. 
While the invention has been disclosed in its preferred 
forms, it will be apparent to those skilled in the art that many 
modifications, additions, and deletions can be made therein 
without departing from the spirit and scope of the invention 
and its equivalents as set forth in the following claims. For 
example, while dry film was used for analysis, the actual 
solution can be used directly in an attenuated total reflec-
tance (ATR) cell. In this cell, the strong absorption of water 
can be minimized. The different infrared spectral regions of 
the signature of the different bacteria using this method of 
detection have also been identified. 
What is claimed is: 
1. A method for detecting bacteria 
sample comprising the steps of: 
m a biologic fluid 
a. obtaining absorption spectra directly from an uncul-
tured biologic fluid sample; 
b. subtracting absorption spectra of a reference sample 
from the absorption spectra of the biologic fluid sample 
to form a differential spectra; 
c. analyzing the differential spectra to detect the presence 
of bacteria in the sample. 
2. The method of claim 1, further comprising the step of: 
d. identifying bacteria detected in the biologic fluid 
sample by comparing the differential spectra with ref-
erence spectra of bacteria. 
3. The method of claim 1, wherein the absorption spectra 
is obtained in the regions selected from the group consisting 
of ultraviolet (UV), visible and infrared (IR). 
US 6,379,920 Bl 
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4. The method of claim 1, wherein the absorption spectra 
is obtained using an instrument selected from the group 
consisting of a Fourier transform infrared spectrometer, a 
fluorometer and a Raman spectrometer. 
5. The method of claim 2, wherein the reference spectra 
is spectra of bacteria selected from the group consisting of 
Haemophilus influenzae (HI), Morazella catarrhalis (MC), 
and Streptococcus pneumoniae (SP). 
10 
17. The method of claim 10, wherein the biological fluid 
sample is selected from the group consisting of blood, 
saliva, urine, bile, vaginal secretions, middle ear aspirate, 
pus, pleural effusions, synovial fluid, abscesses, cavity 
5 swabs, and serum. 
18. A method for the in vivo detection of bacteria com-
prising the steps of: 
6. The method of claim 1, wherein the biologic fluid 
sample is selected from the group consisting of a blood, 10 
saliva, urine, bile, vaginal secretions, middle ear aspirate, 
pus, pleural effusions, synovial fluid, abscesses, cavity 
swabs, and serum. 
a. obtaining the absorption spectra of an uncultured bio-
logic fluid sample directly from a body; 
b. subtracting absorption spectra of a reference sample 
from the absorption spectra of the biologic fluid sample 
to form a differential spectra; 
c. analyzing the differential spectra to detect the presence 
of bacteria in the sample. 7. The method of claim 1, wherein the biologic fluid 
sample is contained in fluid from the human body. 
8. The method of claim 2, wherein the identity of the 
bacteria is determined from absorption spectra in the region 
of 700-1800 cm-1 . 
15 19. The method of claim 18, further comprising the step 
of: 
d. identifying bacteria detected in the biologic fluid 
sample by comparing the differential spectra with ref-
erence spectra of bacteria. 9. The method of claim 1, wherein either dry film or an 
attenuated reflectance cell are used for analyzing the sample. 20 
10. A method for decreasing the time for diagnosing a 
bacterial strain infection comprising the steps of: 
20. The method of claim 18, wherein the absorption 
spectra is obtained in the regions selected from the group 
consisting of ultraviolet (UV), visible and infrared (IR). 
21. The method of claim 18, wherein the absorption 
25 
spectra is obtained using an instrument selected from the 
group consisting of a Fourier transform infrared 
spectrometer, a fluorometer and a Raman spectrometer. 
a. obtaining the absorption spectra of an uncultured bio-
logic fluid sample; 
b. subtracting the absorption spectra of a previously-
obtained reference sample from the absorption spectra 
of the uncultured biologic fluid sample to obtain a 
differential spectra; 
c. analyzing the differential spectra to detect the presence 
of bacteria in the sample. 
11. The method of claim 10, further comprising the step 
of: 
d. identifying bacteria detected in the biologic fluid 
sample by comparing the differential spectra with ref-
erence spectra of bacteria. 
12. The method of claim 10, wherein the absorption 
spectra is obtained in the regions selected from the group 
consisting of ultraviolet (UV), visible and infrared (IR). 
13. The method of claim 10, wherein the absorption 
spectra is obtained using an instrument selected from the 
group consisting of a Fourier transform infrared 
spectrometer, a fluorometer and a Raman spectrometer. 
14. The method of claim 11, wherein the reference spectra 
22. The method of claim 19, wherein the reference spectra 
is spectra of bacteria selected from the group consisting of 
30 
Haemophilus influenzae (HI), Morazella catarrhalis (MC), 
and Streptococcus pneumoniae (SP). 
23. The method of claim 18, wherein the biologic fluid 
sample is selected from the group consisting of a blood, 
saliva, urine, bile, vaginal secretions, middle ear aspirate, 
35 
pus, pleural effusions, synovial fluid, abscesses, cavity 
swabs, and serum. 
24. The method of claim 18, wherein the biologic fluid 
sample is contained in fluid from the human body. 
25. The method of claim 19, wherein the identity of the 
bacteria is determined from absorption spectra in the region 
40 
of 700-1800 cm-1 . 
26. A method for diagnosing otitis media comprising the 
steps of: 
is spectra of bacteria selected from the group consisting of 45 
Haemophilus influenzae (HI), Morazella catarrhalis (MC), 
and Streptococcus pneumoniae (SP). 
a. obtaining the absorption spectra directly from an uncul-
tured sample of middle ear aspirate; 
b. subtracting the spectrum of a previously-obtained ref-
erence sample from the spectra of the middle ear 
aspirate; 15. The method of claim 10, wherein either dry film or an 
attenuated reflectance cell are used for analyzing the sample. 
16. The method of claim 11, wherein the identity of the 50 
bacteria is determined from absorption spectra in the region 
of 700-1800 cm-1 . 
c. analyzing the differential spectra to detect the presence 
of bacteria in the sample. 
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